1-11 of 11
Wells A. Messersmith
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B147: Preclinical evaluation of XPO1 inhibition with topoisomerase-I (topo-I) inhibition in colorectal cancer (CRC) cell lines and patient-derived xenograft (PDX) models

Free
Robert W Lentz, Adrian Dominguez, Stacey Bagby, Cameron Binns, Alexis Leal, Sunnie Kim, Sarah Lindsey Davis, Christopher H Lieu, Wells A Messersmith, Todd M Pitts
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B147.
https://doi.org/10.1158/1535-7163.TARG-23-B147
Published: 01 December 2023
View article titled, Abstract B147: Preclinical evaluation of XPO1 inhibition with topoisomerase-I (topo-I) inhibition in colorectal cancer (CRC) cell lines and patient-derived xenograft (PDX) models
Journal Articles

Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology?

Available to Purchase
Robert W. Lentz, Meryl D. Colton, Siddhartha S. Mitra, Wells A. Messersmith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (6): 961–974.
https://doi.org/10.1158/1535-7163.MCT-21-0041
Published: 01 June 2021
View article titled, Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology?
Open the PDF for Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology? in another window
Journal Articles

First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer

Free
Joshua M. Abbott, Qiong Zhou, Hector Esquer, Laura Pike, Travis P. Broneske, Sébastien Rinaldetti, Adedoyin D. Abraham, Dominique A. Ramirez, Paul J. Lunghofer, Todd M. Pitts, Daniel P. Regan, Aik Choon Tan, Daniel L. Gustafson, Wells A. Messersmith, Daniel V. LaBarbera
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2020) 19 (8): 1598–1612.
https://doi.org/10.1158/1535-7163.MCT-20-0106
Published: 04 August 2020
View article titled, First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer
Open the PDF for First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B107: Metabolic reprogramming enhances the efficacy of mTOR inhibition in colorectal cancer

Free
Peter J Klauck, Hayley J Hawkins, Madison Weber, Stacey M Bagby, Christopher H Lieu, Sarah J Hartman, Betelehem W Yacob, Kelly D Sullivan, Monica Brown, Julie A Reisz, Angelo D’Alessandro, Wells A Messersmith, S Gail Eckhardt, Todd M Pitts
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B107.
https://doi.org/10.1158/1535-7163.TARG-19-B107
Published: 01 December 2019
View article titled, Abstract B107: Metabolic reprogramming enhances the efficacy of mTOR inhibition in colorectal cancer
Journal Articles

Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms

Free
Aaron J. Scott, John J. Arcaroli, Stacey M. Bagby, Rachel Yahn, Kendra M. Huber, Natalie J. Serkova, Anna Nguyen, Jihye Kim, Andrew Thorburn, Jon Vogel, Kevin S. Quackenbush, Anna Capasso, Anna Schreiber, Patrick Blatchford, Peter J. Klauck, Todd M. Pitts, S. Gail Eckhardt, Wells A. Messersmith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (10): 2112–2122.
https://doi.org/10.1158/1535-7163.MCT-17-0131
Published: 01 October 2018
View article titled, Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms
Open the PDF for Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms in another window
Includes: Supplementary data
Journal Articles

Abstract B050: Evaluation of TAK-264, a novel antibody-drug conjugate in pancreatic cancer cell lines and patient-derived xenograft models

Free
Anna R. Schreiber, Anna Nguyen, Stacey M. Bagby, Betelehem Yacob, Kevin Quackenbush, Joe L. Guy, Thomas Crowell, Bradley Stringer, Hadi Danaee, Thea Kalebic, Wells A. Messersmith, John J. Arcaroli, Todd M. Pitts
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B050.
https://doi.org/10.1158/1535-7163.TARG-17-B050
Published: 01 January 2018
View article titled, Abstract B050: Evaluation of TAK-264, a novel antibody-drug conjugate in pancreatic cancer cell lines and patient-derived xenograft models
Journal Articles

Abstract A083: A phase Ib study of the combination of MLN0128 (dual TORC1/2 inhibitor) and MLN8237 (Aurora A inhibitor, alisertib) in patients with advanced solid tumors

Free
S. Lindsey Davis, Elaine T. Lam, Bradley R. Corr, Cindy L. O'Bryant, Ashley Glode, Nichole Adler, Todd M. Pitts, John J. Tentler, Anna Capasso, Kyrie Dailey, Natalie J. Serkova, Colin D. Weekes, Daniel L. Gustafson, Christopher H. Lieu, Wells A. Messersmith, Stephen Leong, S. Gail Eckhardt, Jennifer R. Diamond
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A083.
https://doi.org/10.1158/1535-7163.TARG-17-A083
Published: 01 January 2018
View article titled, Abstract A083: A phase Ib study of the combination of MLN0128 (dual TORC1/2 inhibitor) and MLN8237 (Aurora A inhibitor, alisertib) in patients with advanced solid tumors
Journal Articles

Abstract A012: Humanized patient-derived xenografts (PDXs) recapitulate clinical responses in microsatellite stable (MSS) and unstable (MSI-H) colorectal cancer (CRC)

Free
Anna Capasso, Julie Lang, Todd M. Pitts, Christopher H. Lieu, Scott Kopetz, Sarah L. Davis, Kimberly Jordan, Stacey M. Bagby, Wells A. Messersmith, Roberta Pelanda, S. Gail Eckhardt
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A012.
https://doi.org/10.1158/1535-7163.TARG-17-A012
Published: 01 January 2018
View article titled, Abstract A012: Humanized patient-derived xenografts (PDXs) recapitulate clinical responses in microsatellite stable (MSS) and unstable (MSI-H) colorectal cancer (CRC)
Journal Articles

Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras–Mutated Colorectal Cancer

Free
John J. Tentler, Sujatha Nallapareddy, Aik Choon Tan, Anna Spreafico, Todd M. Pitts, M. Pia Morelli, Heather M. Selby, Maria I. Kachaeva, Sara A. Flanigan, Gillian N. Kulikowski, Stephen Leong, John J. Arcaroli, Wells A. Messersmith, S. Gail Eckhardt
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (12): 3351–3362.
https://doi.org/10.1158/1535-7163.MCT-10-0376
Published: 14 December 2010
View article titled, Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras–Mutated Colorectal Cancer
Open the PDF for Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras–Mutated Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts

Free
Wells A. Messersmith, N.V. Rajeshkumar, Aik Choon Tan, Xiao Fei Wang, Veronica Diesl, Sung E. Choe, Max Follettie, Christina Coughlin, Frank Boschelli, Elena Garcia-Garcia, Fernando Lopez-Rios, Antonio Jimeno, Manuel Hidalgo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (6): 1484–1493.
https://doi.org/10.1158/1535-7163.MCT-09-0075
Published: 10 June 2009
View article titled, Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts
Open the PDF for Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts in another window
Includes: Supplementary data
Journal Articles

Assessment of celecoxib pharmacodynamics in pancreatic cancer

Free
Antonio Jimeno, Maria Luz Amador, Peter Kulesza, Xiaofei Wang, Belen Rubio-Viqueira, Xiangfeng Zhang, Audrey Chan, Jenna Wheelhouse, Hidekazu Kuramochi, Koji Tanaka, Kathleen Danenberg, Wells A. Messersmith, Virna Almuete, Ralph H. Hruban, Anirban Maitra, Charles J. Yeo, Manuel Hidalgo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (12): 3240–3247.
https://doi.org/10.1158/1535-7163.MCT-06-0565
Published: 15 December 2006
View article titled, Assessment of celecoxib pharmacodynamics in pancreatic cancer
Open the PDF for Assessment of celecoxib pharmacodynamics in pancreatic cancer in another window